Why the study?
Does chronic L-arginine administration reduce plasma ET-1 levels and attenuate ET-1-induced vasoconstriction in STZ-induced diabetic rats?
Does chronic L-arginine administration reduce plasma ET-1 levels and attenuate ET-1-induced vasoconstriction in STZ-induced diabetic rats?
Chronic L-arginine administration reduces elevated plasma ET-1 levels and attenuates ET-1-induced vasoconstriction in diabetic rats, suggesting potential therapeutic value for diabetes-related vascular complications.
Supports preclinical rationale in diabetic rats; leaves open translation to human vascular complications.
To investigate the mechanism underlying increased endothelin-1 (ET-1) release in diabetic rats, we administered L-arginine chronically to streptozotocin (STZ)-induced diabetic rats. The plasma concentrations of glucose, ET-1 and NOx (NO2- + NO3-) were all significantly raised at 10 weeks after the STZ injection. Chronic administration of L-arginine resulted in a significantly higher plasma NOx concentration and a significantly lower plasma ET-1 level at 10 weeks compared with the untreated diabetic group. ET-1 induced a biphasic vasodilator/vasoconstrictor response in the perfused isolated mesenteric arterial beds from all groups. The vasodilatation was significantly greater in diabetic rats than in age-matched controls. Chronic oral L-arginine administration had no significant effect on the enhanced ET-1-induced vasodilatation seen in the untreated diabetic rats. The vasoconstrictions induced by ET-1 and methoxamine were significantly attenuated in STZ-diabetic rats. The attenuated vasoconstrictor response to ET-1, but not that to methoxamine, was further attenuated by chronic treatment with L-arginine. We conclude that since chronic L-arginine administration not only reduced the increase in plasma ET-1 levels but also further attenuated the ET-1-induced vasoconstriction without affecting the change in vasodilatation, chronic L-arginine administration could be valuable for the treatment of the symptoms of diabetic mellitus related to ET-1.
No takes yet. Share an insight, caveat, or question.
Makino et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: